Johnson & Johnson Stands Out as a Reliable Dividend Stock

Investors seeking a reliable dividend stock that can withstand economic downturns should consider Johnson & Johnson (NYSE: JNJ). Healthcare stocks, including J&J, are known for their resilience during recessions because demand for medical products and services remains steady.

With 64 consecutive years of dividend growth, Johnson & Johnson is a Dividend King. The company has prioritized operational growth by focusing on faster-growing segments like hematology, which supports its ability to maintain and increase dividends. Analysts estimate earnings of $11.08 per share for 2026, with a forward payout ratio of under 50%, indicating sustainability.

Johnson & Johnson offers a modest yield of 2.1% and mid-single-digit annual payout growth. While these numbers may not be flashy, they reflect a steady approach to long-term investing success. The stock trades at around 21 times forward earnings, suggesting a balanced valuation.

The Motley Fool Stock Advisor team did not include Johnson & Johnson in their top 10 stock picks, highlighting other potential high-growth opportunities. However, J&J remains a strong choice for investors looking for stability and consistent returns.